- $304.51m
- $478.50m
- $114.20m
Agenus Inc reports results for the quarter ended September 30 - Earnings Summary
Agenus Inc expected to post a loss of $2.33 a share - Earnings Preview
Agenus Inc expected to post a loss of $2.33 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Agenus, Guardant Health, Zoetis
Agenus Inc reports results for the quarter ended in June - Earnings Summary
Agenus Inc expected to post a loss of $1.44 a share - Earnings Preview
Brief: Agenus Says Received Notice From Bristol Myers Squibb, It Is Returning Agen1777
Agenus drops after brokerages cut rating; FDA blocks cancer therapy accelerated approval
U.S. STOCKS ON THE MOVE-Allstate, Quanta, First Industrial Realty
U.S. STOCKS ON THE MOVE-Meta Platforms, Cintas, Toast
Agenus falls as FDA advises against 'accelerated approval' pathway for cancer therapy
Brief: Cancer Therapy Evaluation Program Announces Availability Of Botensilimab For Clinical Studies
Cancer biotechs jump on data ahead of industry meet
Brief: FDA Grants Agenus Type B End-Of-Phase 2 Meeting To Discuss Bot/Bal Therapy For Relapsed Or Refractory Metastatic Colorectal Cancer
Agenus Inc reports results for the quarter ended in March - Earnings Summary
Brief: Ligand And Agenus Enter Into $100 Million Royalty Financing Agreement
Agenus Inc expected to post a loss of $2.83 a share - Earnings Preview
Brief: Agenus Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Agenus Announces Updated Phase 1 Data On BOT/BAL Development In Metastatic MSS Colorectal Cancer